Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,112.62
(
-0.19%
)
US TECH 100
25,851.60
(
-0.39%
)
Dow Jones
49,428.49
(
-0.04%
)
Brent Oil
91.38
(
-1.38%
)
Bitcoin
75,324.22
(
1.98%
)
News Focus
News Focus
Post# of 257428
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 54
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: croumagnon post# 40121

Tuesday, 01/02/2007 5:52:01 PM

Tuesday, January 02, 2007 5:52:01 PM

Post# of 257428
The gutting of DNDN's pipeline due to halting all work on everything but the Provenge BLA, no early-stage PCa trials on the horizon for Provenge, and two financings at $4.50 are perfect examples of why management teams should partner their first drugs even if the deals are not perfect.

At this point, let's all cross our fingers and hope the advisory panel is feeling patient-focused and reasonable that day.

Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today